PERONACI, MARCO
PERONACI, MARCO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub
2018 Piazza, R; Magistroni, V; Redaelli, S; Mauri, M; Massimino, L; Sessa, A; Peronaci, M; Lalowski, M; Soliymani, R; Mezzatesta, C; Pirola, A; Banfi, F; Rubio, A; Rea, D; Stagno, F; Usala, E; Martino, B; Campiotti, L; Merli, M; Passamonti, F; Onida, F; Morotti, A; Pavesi, F; Bregni, M; Broccoli, V; Baumann, M; Gambacorti-Passerini, C
Characterization of new oncogenes identified through NGS-based analysis of leukemias: SETBP1 and ETS2-ERG
2017 Peronaci, M
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
2016 Redaelli, S; Ceccon, M; Antolini, L; Rigolio, R; Pirola, A; Peronaci, M; GAMBACORTI PASSERINI, C; Mologni, L
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia
2015 GAMBACORTI PASSERINI, C; Donadoni, C; Parmiani, A; Pirola, A; Redaelli, S; Signore, G; Piazza, V; Malcovati, L; Fontana, D; Spinelli, R; Magistroni, V; Gaipa, G; Peronaci, M; Morotti, A; Panuzzo, C; Saglio, G; Usala, E; Kim, D; Rea, D; Zervakis, K; Viniou, N; Symeonidis, A; Becker, H; Boultwood, J; Campiotti, L; Carrabba, M; Elli, E; Bignell, G; Papaemmanuil, E; Campbell, P; Cazzola, M; Piazza, R
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
2015 Redaelli, S; Ceccon, M; Pirola, A; Peronaci, M; Gambacorti-Passerini, C; Mologni, L
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia
2014 Donadoni, C; Piazza, R; Fontana, D; Parmiani, A; Pirola, A; Redaelli, S; Signore, G; Piazza, V; Malcovati, L; Spinelli, R; Magistroni, V; Gaipa, G; Peronaci, M; Morotti, A; Panuzzo, C; Saglio, G; Elli, E; Usala, E; Kim, D; Rea, D; Zervakis, K; Viniou, N; Symeonidis, A; Becker, H; Boultwood, J; Campiotti, L; Carrabba, M; Bignell, G; Papaemmanuil, E; Campbell, P; Cazzola, M; GAMBACORTI PASSERINI, C